@VJOncology
馃嚞馃嚙Account based in!
About this account
- Account based in
- United Kingdom
- Connected via
- United Kingdom App Store
X says this location may be affected by a proxy or VPN.
Account-level information from X, not a live location or the device used for a specific post.
VJ Oncology retweeted
New standard of care for KRAS G12C mutation positive NSCLC. @FSkoulidis presents Krascendo-1 head to head trial of divarasib vs sotorasib or adagrasib- convincing improving PFS (9.8 m vs 5.7 m, HR 0.58) and OS (17.7m vs 12.0m, HR 0.58)
At #ESMO26, Camilla Nero discusses updated BEHOLD-1 results and biomarkers of mo-rez in #PROC, choosing between #ADCs, and Lynch syndrome testing in #EndometrialCancer
@myESMO #GyncSM #OvarianCancer
At #ESMO26, Piotr Rutkowski (@rutkowskip1972) discusses a detailed safety analysis of varegacestat for desmoid tumors in the phase 3 RINGSIDE trial, how it compares with nirogacestat, and managing long-term toxicity
@myESMO #Sarcoma #DesmoidTumors
馃實 Day 4 at #ESMO26 in Madrid!
Our interviews with leading experts continue as we bring you the latest data and practice updates across #oncology 馃帴
Follow @VJOncology for behind-the-scenes updates, and explore our ESMO 2026 coverage so far馃憠ow.ly/RqL050ZZru2
@myESMO #BCSM #LCSM #PCSM #kcsm #BlcSM #TSCSM #CRCSM #PancSM #ESOCSM #STCsm #HPBCsm #MelSM #SkcSM #scmSM #BTSM #GyncSM #hncSM
VJ Oncology retweeted
Phase 1b combination data for elfetabart drozuntecan (B7H3/Topo-1 ADC) combined with pumitamig (VEGF/PD1 bispecific) shows striking response relates with ~40% G3/4 AEs. Perhaps the best new combination data #ESMO26 . EV + VEGF/PD1 combos are under investigation in bladder cancer too with EV. @OncoAlert
At #WCLC26, Jessy Deshane explores findings from a study examining TROP2 protein and RNA expression in #NSCLC tissue, and how this could inform use of TROP2-targeted ADCs 馃敩馃珌
Watch: ow.ly/Leqa50ZZicY
#Oncology #LungCancer #LCSM @IASLC
#ASCO26 | Tian Zhang (@TiansterZhang) explores evolving treatment sequencing strategies following 1L EV + pembrolizumab in metastatic #BladderCancer, including #resistance mechanisms and alternative ADC targets 馃拤 馃拪
Watch: ow.ly/unKP50ZZibO
#Oncology #UroOnc #BlcSM #ImmunoOnc @ASCO
#ESMO26 | Zev Wainberg discusses subgroup analyses of RASolute 302 of daraxonrasib in metastatic #PancreaticCancer and FGFR2 biomarker analyses of bemarituzumab in FORTITUDE-101/102
@myESMO #GastricCancer #PancSM #TrialUpdates
At #ESMO26, @hongjaechon discusses dose optimization of the GPC3 x 4-1BB #bispecific BGB-B2033 in advanced HCC, the role of bispecifics in #LiverCancer, fostrox plus lenvatinib in second-line HCC, and his #GIcancer highlights 馃帴
@myESMO #LiverCancer #LCSM #ImmunOnc #TrialUpdate
At #ESMO26, Dr Marc Hilmi discusses periostin-expressing CAFs in #PancreaticCancer from PRODIGE 24, how pathogenic ATM loss defines a distinct subgroup, and what this means for KRAS inhibitors like daraxonrasib
@myESMO #PancSM
At #ESMO26 we spoke with Ari Rosenberg (@UCCancerCenter) who discussed emerging strategies for recurrent/metastatic head and neck cancer, including the frontline carboplatin-amivantamab-pembrolizumab triplet now being tested against standard chemoimmunotherapy in an ongoing Phase III trial.
馃帴 tinyurl.com/3zfbtda8
#HNSCC #HeadandNeckCancer @myESMO
VJ Oncology retweeted
Catch #ESMO26 on Video with our collaborators at @VJOncology
Exclusive expert interviews from Madrid break down this year鈥檚 key trials in minutes. Trusted by healthcare professionals worldwide, with 980K+ annual views.
馃憠 Explore the coverage : bit.ly/4jpTaTQ
At #ESMO26, @LorenzaRimassa discusses liver function and post-progression outcomes in EMERALD-3, the GPC3 x 4-1BB bispecific BGB-B2033 in advanced HCC, and 7-year overall survival from HIMALAYA
@myESMO #LiverCancer #HCC #GIsm
#ESMO26 | @PAscierto discusses clinical updates in #cellulartherapies for solid tumors, barriers to adoption in Europe, and first-in-human results of the live biotherapeutic MB097 with pembrolizumab in #melanoma 馃拤馃搱
@myESMO #MelSM #CART #ImmunoOnc
馃敩 Day 3 at #ESMO26!
Our team is onsite in Madrid, hearing from leading experts on the latest trial updates across #oncology 馃ゼ
Follow @VJOncology for exclusive behind-the-scenes footage, and catch up on our recent coverage 馃憞
ow.ly/A1bn50ZZrtt
@myESMO #BCSM #LCSM #PCSM #kcsm #BlcSM #TSCSM #CRCSM #PancSM #ESOCSM #STCsm #HPBCsm #MelSM #SkcSM #scmSM #BTSM #GyncSM #hncSM
At #ESMO26, Joana Ribeiro discusses first results of UNLOCK 14 of short-term preoperative durvalumab in stage I #TNBC, options after neoadjuvant therapy, and the OPT-PEMBRO de-escalation trial
@myESMO #BCSM #BreastCancer #ImmunoOnc @GustaveRoussy
Could whole-transcriptomic profiling identify biomarkers for #metastatis in early-stage #NSCLC? 馃敩
Find out from @RobertoBoreaMD who explores the background for a study with us at #WCLC26 馃И
Watch: ow.ly/XeSX50ZZiaT
#Oncology #LungCancer #LCSM @IASLC #CaGenome
How well do patients with #BreastCancer adhere to a weight loss intervention? 馃攳 馃搲
Find out from Jennifer Ligibel, who explores results from the BWEL trial with us at #ASCO26 馃搳
Watch: ow.ly/4MWs50ZZi9P
#Oncology #SuppOnc #BCSM #TrialUpdate @ASCO @DFCI_BreastOnc
At #ESMO26, Dr Hiroya Taniguchi discusses the phase 3 PRABITAS trial of biweekly vs conventional trifluridine/tipiracil plus bevacizumab in refractory metastatic #ColorectalCancer, and its potential in combination regimens
@myESMO #CRCSM
At #ESMO26, Luigi Lorini discusses results of the phase 2 TEPMEETCET study of EGFR and c-MET inhibition in platinum- and IO-resistant recurrent/metastatic #HeadandNeckCancer, and whether it could move earlier
@myESMO #HNCSM #ImmunoOnc #TrialUpdate @HumanitasMilano
